Structure Therapeutics announces positive results from aleniglipron trial
Aleniglipron showed a tolerability profile that is consistent with the GLP-1 receptor agonist class.
Clinical Trials
Citryll doses first patient in Citylights trial for hidradenitis suppurativa
Eli Lilly reports Phase III trial results of Jaypirca for CLL/SLL
Amylyx presents safety outcomes of AMX0114 in LUMINA study
Pliant Therapeutics reports interim PLN-101095 Phase I trial data
Debiopharm randomises first patient in Phase III acromegaly trial
Rondo Therapeutics begins dosing in Phase I/Ib trial for solid tumours
FDA clears VectorY’s PIONEER-ALS Phase I/II trial for ALS
